Voulez-vous consulter la version mobile de ce site ?

Biography

Jérôme Galon

Jérôme Galon

Dr Jérôme Galon is first class Director of Research at INSERM (French National Institute of Health and Medical Research) and head of an INSERM laboratory (INSERM UMRS1138, Integrative Cancer Immunology) at the Cordeliers Research Center in Paris, France. Dr. Jérôme Galon is the co-founder of the company, HalioDx, and is the Chairman of its scientific council. He is associate Director and co-founder of European Academy of Tumor Immunology (EATI), Board Director of Society for Immunotherapy of Cancer (SITC, USA), member of AAI, SFI, and AACR. He also serves on numerous advisory panels. Dr. Galon was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France). He holds a Ph.D. degree in Immunology (Jussieu University, Paris, France, 1996). Between 1997 and 2001 he worked at the NIH (National Institute of Health, Bethesda, USA) on functional genomics, bioinformatics and immunology on fundamental and clinical research. Since his full-tenured position at INSERM in 2001, he directs interdisciplinary research programs. Dr. Jérôme Galon has made important contributions to medical research through his groundbreaking work in the fields of immunology and cancer research. His contributions have been recognized with numerous awards. He received the prestigious William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (Cancer Research Institute, New York, USA), Award from the National Academy of Science, and Award from the National Academy of Medicine, fellow Award for Research Excellence at NIH (USA), Awards from the French foundation, from the Medical Research Foundation, from the French Society of Immunology (Jacques Oudin Award). He gave the prestigious Annual B. Benacerraf Lecture in Immunology (Harvard, USA, 2014). He is best known for his works on comprehensive analysis of the tumor-microenvironment in human cancer and bioinformatics, and for the discovery that the adaptive immune reaction within the tumor was a better predictor of survival than traditional staging based on cancer's size and spread. He defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. Dr. Galon has published over 150 papers in top-tier scientific journals, and delivered over 250 invited lectures internationally.

Renaud Garrel

Renaud Garrel

Renaud GARREL is the chief of Head Neck Cancer & Laryngology Department at the University Hospital Center of Montpellier. He is head and neck surgeon, Professor of University since 2010, Consultant Physician at the Montpellier Cancer Institute Val d’Aurelle since 2001 and Director of the Logopedics University Department, succeeding Prof. Bernard GUERRIER, his mentor, worldly known as a pioneer in head and neck surgery. His main publications is devoted to detection of minimal cancer spreading of head and neck tumours regarding lymph node especially in sentinel lymph node. He is currently conducting the French randomized study SENTIMER, comparing sentinel node technique with routine neck dissection in T1T2 N0 oral and oropharyngeal squamous cell cancer. Blood dissemination is also an original topic of his investigations with the study of Circulating Tumor Cell in relapsing not operable head neck cancers treated with CETUXIMAB, thanks to his close collaboration with Dr Catherine ALIX PANABIERES through the CIRCUTEC project. He was granted more than two million of euros to conduct these researches during last decade. Prof. GARREL is glad and very honoured to be an invited as speaker at the ISMRC conference, held in his natal town and behalf of the organizing committee, welcome everyone to the congress.

Paola Gazzaniga

Paola Gazzaniga

Professor of Molecular Oncology at Dept. Molecular Medicine, Sapienza University of Rome. Her involvement in liquid biopsy research stems from her experience in molecular pathology and abilities in the molecular characterization of tumor cells. In the last 10 years she published more than 20 papers on the molecular portrait of CTCs, demonstrating the importance of epithelial-mesenchymal transition in CTCs. She also published for the first time about the use of CTCs as predictive biomarkers of response to cancer immunotherapy. She is involved in international working groups that are dealing with the demonstration of the clinical utility of liquid biopsy. Her research is currently focused to the non-invasive monitoring of colorectal cancer molecular evolution over the course of therapies through ctDNA analysis. She is highly committed to pursue the aim of achieving definitive level of evidence for the clinical applicability of liquid biopsies .

Christine Gilles

Christine Gilles

Christine Gilles received her PhD in Science in 1994 at the University of Liège in Belgium. Along the way, she gained increasing interest in Epithelial-to-Mesenchymal Transitions. She therefore joined the laboratory of Professor Rik Thompson at Georgetown University (Washington DC) for a 3 year post-doc to deepen her knowledge in this particular field. Coming back to her home University, she was given tenure as a Research Associate at the FNRS (Fonds National de la Recherche Scientifique, Belgium). In 2008, she was promoted to a Senior Research Associate position at the FNRS. She is today the principal investigator of an EMT-research team at the University of Liège deciphering mechanisms of EMT implicated in metastasis, and has (co-)authored 63 international peer-reviewed publications in the field. Most recently, she initiated a research axis that originally emphasized a role for EMT pathways in providing CTCs with coagulant properties, thereby facilitating early metastasis.

Daniel Hayes

Daniel Hayes

Daniel F. Hayes, MD, FASCO, FACP Dr. Daniel F. Hayes is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, where he is the Stuart B. Padnos Professor of Breast Cancer Research. Dr. Hayes received bachelor’s, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Health Science Center/Parkland Memorial Hospital from 1979 to 1982. After a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI) from 1982 to 1985, he remained on faculty and was the Medical Director of the Breast Evaluation Center at DFCI from 19912-1996. He subsequently became the Director of the Breast Cancer Program at Georgetown University’s Lombardi Cancer Center from 1996 to 2001, when he moved to the University of Michigan.

Paul Hofman

Paul Hofman

Paul Hofman obtained his MD degree in 1989 at the University of Nice Sophia Antipolis (France) and his PhD degree in 1994 at the University of Montpellier I (France). He did research fellows first at the Brigham and Women’s Hospital (Boston, Harvard Medical School) from 1992 to 1996 and then at the Max Planck Institut (Tubingen). He is full professor of pathology since 1995 and head of a research team at the Inserm 1081/UMR CNRS 7284 (IRCAN), Labex Signalife member, located at the Comprehensive Cancer Center of Nice University. The main topic of this team is related to lung cancer pathophysiology and to biomarkers discovery. He is the head of the Hospital-related Biobank (BB-0033-00025) and of the Laboratory of Clinical and Experimental Pathology at Nice Hospital (Idex Jedi, University of Nice Côte d’Azur). He is the director of the OncoAge FHU (www.oncoage.org).

Dave S.B. Hoon

Dave S.B. Hoon

Dave S.B. Hoon, Professor and Director of Dept. of Molecular Oncology, and Chief of Scientific Intelligence at the John Wayne Cancer Institute, interacts with external academic, industry, government agencies, and international cancer centers to develop innovative translational cancer research opportunities. He has over 30 patents on his studies and has co-authored over 300 peer-reviewed articles and reviews, primarily related to translational molecular oncology of human solid tumors. As founding Director of the Department of Molecular Oncology, Dr. Hoon continues to pioneer investigations of RNA/genomic/epigenomic biomarkers for diagnostic, prognostic and predictive assessment of residual tumor cells. Dr. Hoon pioneered investigations of CTC and circulating cell-free DNA/miRNA biomarkers for monitoring cancer in patients enrolled in phase II/III clinical trials. Since early 1990’s Dr. Hoon’s team has developed molecular biomarkers for molecular staging of sentinel lymph nodes and classification of human solid tumors including CRC, melanoma and breast cancer. In the last decade he and his team have developed programs for assessment of epigenetic regulatory pathways of aggressive breast cancers (TNBC). On the therapeutic front, Dr. Hoon is examining functional epigenomic drugs for treatment approaches for solid tumor cancers. Dr. Hoon has trained over 70 fellows and a dozen graduate students.

Wolfgang Janni

Wolfgang Janni

Wolfgang Janni, MD, PhD, is currently a full professor and director in the Department of Obstetrics and Gynecology at the University of Ulm in Germany. He was appointed to this position in October 2012 after working as a full professor and director of the Department of Obstetrics and Gynecology at the Heinrich-Heine-University in Duesseldorf, Germany, from 2008 until 2012. He received the credentials for professorship at Munich University in 2015, but decided to stay in Ulm. In 2016, he was appointed as chair of the German Guideline Council for Breast Cancer (AGO). His two main areas of research include the relevance of liquid biopsy in patients with breast cancer and clinical research. His research has received numerous international awards. He is author or co-author of 213 publications in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer.

Stefanie Jeffrey

Stefanie Jeffrey

Dr. Jeffrey is the John and Marva Warnock Professor and Chief of Surgical Oncology Research at Stanford University School of Medicine. She received her undergraduate degree in Chemistry and Physics and master’s degree in Chemistry, both from Harvard University, and graduated from medical school at University of California San Francisco (UCSF), where she also completed her surgical residency. Dr. Jeffrey was a key member of the Stanford-Norway team that pioneered the transcriptional profiling of breast cancer that first classified breast tumors into distinct molecular subtypes. She later led a multidisciplinary team that invented a device that captures highly purified live CTCs for single cell profiling. Her lab focuses on technology development and applications related to CTCs, metastasis formation, and preclinical patient-derived models for testing cancer therapies. She is Co-Chair of the 2018 Gordon Research Conference on Liquid Biopsy for Cancer and serves on the Scientific Advisory Board of the EU liquid biopsy program, CANCER-ID.

Raghu Kalluri

Raghu Kalluri

Raghu Kalluri was born in St. Louis, Missouri. He received his B.S. in Chemistry and Genetics, then earned his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center, and then received his M.D. degree from Brown University Medical School. Dr. Kalluri was a postdoctoral fellow and a research associate at the University of Pennsylvania Medical School and performed research in areas of immunology and organ fibrosis. In 1997, Dr. Kalluri moved to Harvard Medical School as an Assistant Professor of Medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. In 2000, he was named Associate Professor and the Director of the Center for Matrix Biology. In 2006, this program became the Division of Matrix Biology and Dr. Kalluri was appointed the Chief of the Division and promoted to Professor of Medicine at Harvard Medical School. He held appointments in the Department of Biological Chemistry and Molecular Pharmacology at HMS, Harvard MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute and was a research fellow of the HMS Peabody Society. In 2012, Dr. Kalluri moved to The University of Texas MD Anderson Cancer Center as the Chairman and Professor of the Department of Cancer Biology and the Director of the Metastasis Research Center. Dr. Kalluri currently holds the RE Bob Smith Distinguished Chair for Cancer Biology and previously held the Olla S. Stribling Distinguished Chair in Cancer Research and the Rebecca and Joseph Brown Endowed Chair at MD Anderson Cancer Center. In 2015 Dr. Kalluri received the Jacob Henle Medal from the Georg-August University in Germany to honor his contribution to medical research. He is the recipient of several mentorship and teaching awards from the Beth Israel Deaconess Medical Center and Harvard Medical School. He is also the recipient of research excellence awards for his work on basement membranes and extracellular matrix as related to fibrosis and cancer progression. He is the fellow of American Society of Clinical Investigation and the American Association for the Advancement of Science (AAAS). Dr. Kalluri has published over 287 peer- reviewed manuscripts. Dr. Kalluri has trained 73 postdoctoral fellows, 11 graduate students, and 56 undergraduate students, and fifty-one of his trainees hold academic positions around the world. Dr. Kalluri teaches 1st year core courses for graduate students and medical students. He serves on science and health advisory panels in the USA and European Union and on the editorial boards of several academic journals representing biology and medicine. His laboratory is broadly interested in the study of cell/tissue microenvironment and its impact on cancer progression and metastasis, and tissue injury and repair.


La Région OCCITANIE
Congress date : May 3-5 2018

Organizing committee

Catherine Alix-Panabières
Klaus Pantel

Download Programme

Programme

Important
Dates

  • 15th December 2017
    End of the early registration fees
  • 1st February 2018
    Abstract submission deadline
  • 22nd March 2018
    Notification of abstract acceptance & Travel awards
  • 15th April 2018
    End of the standard registration fees
  • 3rd May 2018
    Opening of the ISMRC 2018

Photo
gallery

Montpellier Go to the gallery